Kelayakan Multimedia Interaktif Berbasis Adobe Flash pada Sub Materi Gangguan Kesehatan Reproduksi

This research aims to know the feasibility of interactive multimedia using adobe flash based on survey of adolescent reproductive system disorders in Puskesamas Alianyang Pontianak. Method was used descriptive quantitative research with technique purposive sampling. Interactive multimedia validated by five media and material experts. Aspect assessed include aspect of software engineering, learning design, and audio-visual communication. The average result of interactive multimedia validation analized found that the aspects of software engineering was 3,70, learning design was 3,62, and audiovisual communication was 3,52. Interactive multimedia using adobe flash was applicable to used as learning media

The Clean Development Mechanism (CDM): constraints and opportunities for the Sabah forestry sector

Brief accounts of the recent development in the international negotiations of the climatic treaty as well as the stand and efforts on climate change issue done at the federal and state level with regard to the forestry sector are given. Ineligibility of funding for forestry carbon projects under the current rules of the Clean Development Mechanism (CDM) is seen as a major constraint for the forestry sector to play an influential role in combating climate change. Non-CDM funding may provide a short-term solution to the already constricted financial situations in the forestry sector. Capacity building of the Sabah Forestry Department is seen as a viable opportunity to be taken up by this seminar

Hubungan Luas Infark Miokard (Berdasar Skor Selvester) Dengan Respon Nyeri Dada Pada Pasien Sindrom Koroner Akut (Ska) Di Rsd Dr. Soebandi Jember

Kegawatan penyakit jantung pada Sindrom Koroner Akut (SKA) bersifat progresif yang mencakup angina tidak stabil, ST-elevation myocardial infarction (STEMI) dan non-ST elevation myocardial infarction (NSTEMI). Diagnosis SKA berdasar 3 komponen yang harus ditemukan yakni: gejala iskemia sakit dada, Perubahan elektokardiografi (EKG) dan peningkatan enzim jantung. Penggunaan Selvester skore dapat menentukan luas dan lokasi infark miokard karena dapat menilai Perubahan depolarisasi ventrikel. Penelitian bertujuan mengetahui adanya hubungan antara luas infark miokard (berdasar skor Selvester) dengan respon nyeri dada pada pasien SKA. Penelitian ini termasuk analitik observasional dengan desain Cross Sectional dan teknik pengambilan sampel consecutive sampling dengan sampel 20 responden. Hasil analisa menggunakan uji statistik Regresi Logistik menunjukkan luas infark miokard memiliki pengaruh signifikan pada model jenis respon nyeri sedang dan berat dengan nilai p: 0.045 untuk nyeri sedang dan nilai p: 0.019 untuk nyeri berat. Hasil penelitian tersebut dapat disimpulkan bahwa semakin luas infark miokard akan semakin berat nyeri dada yang dirasakan pasien dengan SKA

Factors affecting haemoglobin dynamics in African children with acute uncomplicated Plasmodium falciparum malaria treated with single low dose primaquine or placebo

Background: Single low-dose primaquine (SLDPQ) effectively blocks the transmission of Plasmodium falciparum malaria, but anxiety remains regarding its haemolytic potential in patients with glucose-6-phopshate dehydrogenase (G6PD) deficiency. We, therefore, examined the independent effects of several factors on haemoglobin (Hb) dynamics in falciparum-infected children with a particular interest in SLDPQ and G6PD status. Methods: This randomised, double-blind, placebo-controlled, safety trial was conducted in Congolese and Ugandan children aged 6 months–11 years with acute uncomplicated P. falciparum and day (D) 0 Hbs ≥ 6 g/dL who were treated with age-dosed SLDPQ/placebo and weight-dosed artemether lumefantrine (AL) or dihydroartemisinin piperaquine (DHAPP). Genotyping defined G6PD (G6PD c.202T allele), haemoglobin S (HbS), and α-thalassaemia status. Multivariable linear and logistic regression assessed factor independence for continuous Hb parameters and Hb recovery (D42 Hb > D0 Hb), respectively. Results: One thousand one hundred thirty-seven children, whose median age was 5 years, were randomised to receive: AL + SLDPQ (n = 286), AL + placebo (286), DHAPP + SLDPQ (283), and DHAPP + placebo (282). By G6PD status, 284 were G6PD deficient (239 hemizygous males, 45 homozygous females), 119 were heterozygous females, 418 and 299 were normal males and females, respectively, and 17 were of unknown status. The mean D0 Hb was 10.6 (SD 1.6) g/dL and was lower in younger children with longer illnesses, lower mid-upper arm circumferences, splenomegaly, and α-thalassaemia trait, who were either G6PDd or heterozygous females. The initial fractional fall in Hb was greater in younger children with higher D0 Hbs and D0 parasitaemias and longer illnesses but less in sickle cell trait. Older G6PDd children with lower starting Hbs and greater factional falls were more likely to achieve Hb recovery, whilst lower D42 Hb concentrations were associated with younger G6PD normal children with lower fractional falls, sickle cell disease, α-thalassaemia silent carrier and trait, and late treatment failures. Ten blood transfusions were given in the first week (5 SLDPQ, 5 placebo). Conclusions: In these falciparum-infected African children, posttreatment Hb changes were unaffected by SLDPQ, and G6PDd patients had favourable posttreatment Hb changes and a higher probability of Hb recovery. These reassuring findings support SLDPQ deployment without G6PD screening in Africa

Safety of age-dosed, single low-dose primaquine in children with glucose-6-phosphate dehydrogenase deficiency who are infected with Plasmodium falciparum in Uganda and the Democratic Republic of the Congo: a randomised, double-blind, placebo-controlled, non-inferiority trial

Background WHO recommends gametocytocidal, single low-dose primaquine for blocking the transmission of Plasmodium falciparum; however, safety concerns have hampered the implementation of this strategy in sub-Saharan Africa. We aimed to investigate the safety of age-dosed, single low-dose primaquine in children from Uganda and the Democratic Republic of the Congo. Methods We conducted this randomised, double-blind, placebo-controlled, non-inferiority trial at the Mbale Regional Referral Hospital, Mbale, Uganda, and the Kinshasa Mahidol Oxford Research Unit, Kinshasa, Democratic Republic of the Congo. Children aged between 6 months and 11 years with acute uncomplicated P falciparum infection and haemoglobin concentrations of at least 6 g/dL were enrolled. Patients were excluded if they had a comorbid illness requiring inpatient treatment, were taking haemolysing drugs for glucose-6-phosphate dehydrogenase (G6PD) deficiency, were allergic to the study drugs, or were enrolled in another clinical trial. G6PD status was defined by genotyping for the G6PD c.202T allele, the cause of the G6PD-deficient A− variant. Participants were randomly assigned (1:1) to receive single low-dose primaquine combined with either artemether–lumefantrine or dihydroartemisinin–piperaquine, dosed by bodyweight. Randomisation was stratified by age and G6PD status. The primary endpoint was the development of profound (haemoglobin <4 g/dL) or severe (haemoglobin <5 g/dL) anaemia with severity features, within 21 days of treatment. Analysis was by intention to treat. The sample size assumed an incidence of 1·5% in the placebo group and a 3% non-inferiority margin. The trial is registered at ISRCTN, 11594437, and is closed to new participants. Findings Participants were recruited at the Mbale Regional Referral Hospital between Dec 18, 2017, and Oct 7, 2019, and at the Kinshasa Mahidol Oxford Research Unit between July 17, 2017, and Oct 5, 2019. 4620 patients were assessed for eligibility. 3483 participants were excluded, most owing to negative rapid diagnostic test or negative malaria slide (n=2982). 1137 children with a median age of 5 years were enrolled and randomly assigned (286 to the artemether–lumefantrine plus single low-dose primaquine group, 286 to the artemether–lumefantrine plus placebo group, 283 to the dihydroartemisinin–piperaquine plus single low-dose primaquine group, and 282 to the dihydroartemisinin–piperaquine plus placebo group). Genotyping of G6PD identified 239 G6PD-c.202T hemizygous males and 45 G6PD-c.202T homozygous females (defining the G6PD-deficient group), 119 heterozygous females, 418 G6PD-c.202C normal males and 299 G6PD-c.202C normal females (defining the non-G6PD-deficient group), and 17 children of unknown status. 67 patients were lost to follow-up and four patients withdrew during the study—these numbers were similar between groups. No participants developed profound anaemia and three developed severe anaemia: from the G6PD-deficient group, none (0%) of 133 patients who received placebo and one (0·66%) of 151 patients who received primaquine (difference −0·66%, 95% CI −1·96 to 0·63; p=0·35); and from the non-G6PD-deficient group, one (0·23%) of 430 patients who received placebo and one (0·25%) of 407 patients who received primaquine (−0·014%, −0·68 to 0·65; p=0·97). Interpretation Gametocytocidal, age-dosed, single low-dose primaquine was well tolerated in children from Uganda and the Democratic Republic of the Congo who were infected with P falciparum, and the safety profile of this treatment was similar to that of the placebo. These data support the wider implementation of single low-dose primaquine in Africa. Funding UK Government Department for International Development, UK Medical Research Council, UK National Institute for Health Research, and the Wellcome Trust Joint Global Health Trials Scheme